Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity

Histology and Histopathology

Volumn 24, Issue 2, 2009, Pages 197-207

  Pettus, Jason R ^a   Johnson, Jeffrey J ^a   Shi, Zonggao ^a   Davis, J Wade ^a   Koblinski, Jennifer ^b   Ghosh, Supurna ^b   Liu, Yueying ^a   Ravosa, Matthew J ^a   Frazier, Shellaine ^a   Stack, M Sharon ^a  

^a University of Missouri   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Kallikrein; Oral cancer; Squamous cell carcinoma

Indexed keywords

COMPLEMENTARY DNA; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 5; NEUROPSIN; PROSTATE SPECIFIC ANTIGEN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; KLK10 PROTEIN, HUMAN; KLK5 PROTEIN, HUMAN; KLK7 PROTEIN, HUMAN; KLK8 PROTEIN, HUMAN;

ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MOUTH CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MOUTH TUMOR; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

MURINAE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 59149105913     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Benjamini Y. and Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Statistical Society Series B, 57, 289-300.
2. Borgono C.A., Iacovos P.M. and Eleftherios P.D. (2004). Human tissue kallikreins: Physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
3. Borgono C.A., Michael I.P., Komatsu N., Jayakumar A., Kapadia R., Clayman G.L., Sotiropoulou G. and Diamandis E.P. (2007). A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282,3, 640-652.
4. Caubet C., Jonca N., Brattsand M., Guerrin M., Bernard D., Schmidt R., Egelrud T., Simon M. and Sere G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122, 1235-1244.
5. Clements J.A., Willemsen N.M., Myers S.A. and Dong Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
6. Darling M.R., Tsai S., Jackson-Boeters L., Daley T.D. and Diamandis E.P. (2006). Human kallikrein 3 and human kallikrein 5 expression in salivary gland tumors. Int. J. Biol. Markers 21, 201-205.
7. Deraison C., Bonnart C., Lopez F., Besson C., Robinson R., Jayakumar A., Wagberg F., Brattsand M., Hachem J.P., Leonardsson G. and Hovnanian A. (2007). LEKTI fragments specifically inhibit KLK5, KLK7 and KLK14 and control desquamation through a pH dependent interaction. Mol. Biol. Cell 18, 3607-3619.
8. Descargues P., Deraison C., Prost C., Fraitag S., Mazereeuw-Hautier, J., D'Alessio M., Ishida-Yamamamoto A., Bodemer C., Zambruno G. and Hovnanian A. (2006). Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin-and chymotrypsinhyeractivity in Netherton syndrome. J. Invest. Dermatol. 126, 1622-1632.
9. Descargues P., Deraison C., Bonnart C., Kreft M., Kishibe M., Ishida-Yamamoto A., Elias P., Barrandon Y., Zambruno G., Sonnenberg A. and Hovnanian A. (2005). Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nature Genetics 37, 56-63.
10. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G., Tierney L., Yang J.Y. and Zhang J. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80
11. Ghosh S., Brown R., Jones J.C.R., Ellerbroek S.M. and Stack M.S. (2000). Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by α3β1 integrin in oral keratinocytes. J. Biol. Chem. 275, 23869-23876.
12. Ghosh S., Johnson J.J., Sen R., Mukhopadhyay S., Liu Y., Zhang F., Wei Y., Chapman, H.A. and Stack M.S. (2006). Functional relevance of urinary-type plasminogen activator receptor-α3β1 integrin association in proteinase regulatory pathways. J. Biol. Chem. 281, 13021-13029.
13. Ghosh S., Koblinski J., Johnson J., Liu Y., Frazier S., Ericcson, A., Shi. Z., Ravosa M.J., Crawford S., and Stack M.S. Urinary-type plasminogen activator receptor (uPA/R)/α3β1 Integrin Signaling and Oral Tumor Progression (in review).
14. Hundsdorfer B., Zeilhofer H. F., Bock K. P., Dettmar P., Schmitt M., Kolk A., Pautke C. and Horch H.H. (2005). Tumor associated urokinase type plasminogen activator and its inhibitor PAI1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J. Craniomaxillofac. Surg.. 33, 191-196.
15. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. and Thun M.J. (2006). Cancer statistics, CA: A Cancer Journal for Clinicians 56, 106-130.
16. Lindberg P., Larsson A. and Nielsen B.S. (2006). Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma 2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int. J. Cancer 118, 2948-2956.
17. Macfarlane G.I., Boyle P., Evstifeeva T.V., Robertson C. and Scully C. (1994). Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. Cancer Causes Control 5, 2259-2265.
18. Michael I.P., Pampalkis G., Miklajczyk S.D., Malm J., Sotiropoulou G. and Diamandis E.P. (2006). Human tissue kallikrein 5 is a member of a proteolytic cascasde pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 281, 12743-12750.
19. Myers J.N., Holsinger F.C., Jasser S.A., Bekele B.N. and Fidler I.J. (2002). An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clinic. Cancer Res. 8, 293-298
20. Nagata M., Fujita H., Ida H., Hoshina H., Inoue T., Seki Y., Ohnishi M., Ohyama T., Shingaki S., Kaji M., Saku T. and Takagi R. (2003). Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int. J. Cancer 106, 683-689.
21. Nozaki S., Endo Y., Kawashiri S., Nakagawa K., Yamamoto E., Yonemura Y. and Sasaki T. (1998). Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol. 34, 58-62.
22. Oikonomopoulou K., Hansen K.K., Saifedine M., Tea I., Blabber M., Blabber S.I., Scarisbrick I., Andrade-Gordon P., Cottrell G.S., Bunnett N.W., Diamandis E.P. and Hollenberg M.D. (2005). Protease activated receptors: targets for kallikrein signaling. J. Biol. Chem. 281, 32095-32112.
23. Paliouras M., Borgono C. and Diamandis E.P. (2004). Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 249, 61-79.
24. Pampalakis G. and Sotiropoulou G. (2007). Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 1776, 22-31.
25. Parkin D.M., Pisani P. and Ferlay J. (1999). Global cancer statistics. CA: A Cancer Journal for Clinicians 49, 33-64.
26. Sano D. and Myers J.N. (2007). Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 26, 645-662.
27. Santin A.D., Cane S., Bellone S., Bignotti E., Palmieri M., De Las Casas L.E., Roman J.J., Anfossi S., O'Brien T. and Pecorelli S. (2004). The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in cervical cancer cells. Gyn. Oncol. 2094, 283-88.
28. Santin A.D., Diamandis E.P., Bellone S., Marizzoni M., Bandiera E., Palmieri M., Papasakelariou C., Katsaros D., Burnett A. and Pecorelli S. (2006). Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am. J. Ob. Gyn. 194, 1296-1302.
29. Shi Z. and Stack M.S. (2007). Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem. J. 407, 153-159.
30. Smyth G.K. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3, Article 3 http://www.bepress.com/sagmb/vol3/iss1/art3.
31. Smyth G.K. (2005). Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and bioconductor. Gentleman R., Carey V., Dudoit S., Irizarry R. and Huber W. (eds). Springer. New York. pp 397-420.
32. Yang Y. H., Dudoit S., Luu P., Lin D. M., Peng V., Ngai J. and Speed T. P. (2002). Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30, e15.
33. Yasuda T., Sakata Y., Kitamura K., Morita M. and Ishida T. (1997). Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck 19, 611-616.
34. Ye H., Yu T., Temam S., Ziober B.L., Wang J., Schwartz J.L., Mao L., Wong D.T. and Zhou X. (2008). Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 6, 69-79.
35. Ziober A.F., Patel K.R., Alawi F., Gimotty P.H., Weber R.S., Feldman M.M., Chalian A.A., Weinstein G.S., Hunt J. and Ziober B.L. (2006). Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin. Can. Res. 12, 5960-5971.